BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.

Autologous stem cell transplant (ASCT) has been shown to be an effective treatment for follicular lymphoma (FL).

We explored our experience in ASCT for FL among all patients treated over a 15-year period from diagnosis through their entire treatment history including relapse post ASCT.

The median OS from diagnosis was 16 years for the FL-NT.

Unpurged ASCT is an effective tool in the treatment of relapsed, aggressive FL-NT and FL-T, is superior to retreatment with standard chemotherapy, is effective at various stages of treatment, is likely to have a beneficial influence on the natural history of this disease, and the disease is amenable to salvage therapy post-ASCT relapse.

[MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoma, Follicular / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy / methods

[MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Ontario. Retrospective Studies. Transplantation, Autologous / methods

Genetic Alliance. consumer health - Follicular Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17640600.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.

We examined retrospectively 44 patients with refractory acute leukemia (acute myeloid leukemia (AML)/acute lymphoblastic leukemia=25/19) who underwent allogeneic transplantation at our center between 11/1990 and 04/2004.

All patients had graft-versus-host disease (GVHD) prophylaxis with cyclosporin and methotrexate.

Severe acute-GVHD and chronic-GVHD appeared in eight and 14 patients, respectively.

We conclude that patients with refractory leukemia can benefit from allogeneic BMT, especially with < or =20% marrow blast.

[MeSH-major] Blast Crisis / therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning

[MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Retrospective Studies. Transplantation, Homologous. Whole-Body Irradiation / methods

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. BUSULFAN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16258531.001).

[ISSN] 0268-3369

[Journal-full-title] Bone marrow transplantation

[ISO-abbreviation] Bone Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.

Eighteen patients with hematologic malignancies underwent cord blood transplantation (CBT) from unrelated donors after being conditioned with myeloablative or reduced-intensity regimens, and received tacrolimus and methotrexate (15 mg/m(2) on day 1, 10 mg/m(2) on days 3 and 6) as graft-versus-host disease (GVHD) prophylaxis.

Of the 16 evaluable patients, five and eight had grades I and II acute GVHD, respectively, and none had grades III/IV acute GVHD.

The cumulative incidence of grade II acute GVHD was 44.4%.

Of the 18 patients, 14 were alive and disease-free between 173 and 1514 days after CBT (median 746 days).

The probability of disease-free survival at 2 years was 79.1%.

These results, although in a retrospective study, suggested that tacrolimus and short-term methotrexate effectively prevented the occurrence of severe acute GVHD after unrelated CBT, and may contribute to a high survival rate.

[MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Graft vs Host Disease / prevention & control. Hematologic Neoplasms / therapy. Methotrexate / therapeutic use. Tacrolimus / therapeutic use

[MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Immunosuppressive Agents / therapeutic use. Leukemia / therapy. Leukocyte Count. Lymphoma / therapy. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Neutrophils. Probability. Transplantation Conditioning

Genetic Alliance. consumer health - Transplantation.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17580201.001).

[ISSN] 0041-1345

[Journal-full-title] Transplantation proceedings

[ISO-abbreviation] Transplant. Proc.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival.

Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse.

No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia.

DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.

The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy.

In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.

T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.

In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.

CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients.

Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.

[MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

[MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]

[Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]

[Cites] Exp Hematol. 1997 Apr;25(4):312-20 [9131006.001]

[Cites] Leukemia. 1997 May;11(5):639-43 [9180285.001]

[Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]

[Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]

[Cites] EMBO J. 1999 Jul 15;18(14):3990-4003 [10406804.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]

[Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]

[Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]

[Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]

[Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]

[Cites] Haematologica. 2006 Feb;91(2):270-1 [16461320.001]

[Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]

[Cites] Oncogene. 2006 Jul 13;25(30):4217-29 [16518414.001]

[Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]

[Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]

[Cites] Expert Rev Mol Med. 2007;9(14):1-17 [17524167.001]

[Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]

[Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]

[Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]

[Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]

[Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]

[Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]

[Cites] Blood. 2006 Apr 15;107(8):3303-12 [16380455.001]

[Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]

[Cites] Leukemia. 2001 Dec;15(12):1914-22 [11753613.001]

[Cites] Br J Haematol. 2002 Feb;116(2):409-20 [11841446.001]

[Cites] Int J Hematol. 2003 Jun;77(5):463-70 [12841384.001]

[Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]

[Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]

[Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]

[Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]

[Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]

[Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]

[Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]

[Cites] J Biol Chem. 1994 Feb 25;269(8):6198-206 [8119964.001]

[Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]

(PMID = 20435628.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Other-IDs] NLM/ PMC2878792

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The ups and downs of Tax and histones in adult T-cell leukemogenesis.

[MeSH-major] Gene Products, tax / physiology. Histones / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18518755.001).

[ISSN] 1744-8301

[Journal-full-title] Future oncology (London, England)

[ISO-abbreviation] Future Oncol

[Language] eng

[Publication-type] Editorial

[Publication-country] England

[Chemical-registry-number] 0 / Gene Products, tax; 0 / Histones

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Munchausen's syndrome in the allogeneic stem cell transplantation setting: a rare but potentially devastating condition.

[MeSH-major] Munchausen Syndrome / diagnosis. Munchausen Syndrome / psychology. Stem Cell Transplantation / psychology

[MeSH-minor] Female. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous. Young Adult

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19668234.001).

[ISSN] 1476-5365

[Journal-full-title] Bone marrow transplantation

[ISO-abbreviation] Bone Marrow Transplant.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome.

BACKGROUND: Immunophenotypic characterization of the leukemic cells has been widely used as a tool for diagnosis, classification, stratification and prognosis of leukaemia.

OBJECTIVE: To investigate the immunophenotypic subtype profiles of Iranian patients with acute lymphoblastic leukemia (ALL) and its association to disease outcome.

Clinical manifestations and laboratory findings of the patients did not reveal association with immunophenotypic subtypes of ALL, with the exception of mediastinal mass and WBC count at the time of diagnosis which were found to be significantly higher in patients with T-ALL compared with B-ALL (p=0.001 and 0.014), respectively.

CONCLUSION: Our results indicate that overall the immunophenotypic profile of Iranian ALL patients is similar to previous reports and it might be used for monitoring of minimal residual disease and prognosis.

[MeSH-major] Immunophenotyping. Leukemia, B-Cell / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

[MeSH-minor] Adult. Child. Disease Progression. Humans. Iran / epidemiology. Predictive Value of Tests. Recurrence

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17652839.001).

[ISSN] 1735-1383

[Journal-full-title] Iranian journal of immunology : IJI

[ISO-abbreviation] Iran J Immunol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Iran

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distribution, proliferation, and function of Paneth cells in uncomplicated and complicated adult celiac disease.

Because controversies remain concerning Paneth cell numbers and function in celiac disease (CD), we quantified Paneth cells and human alpha-defensin (HD)-5 and HD-6 in 28 patients with uncomplicated CD, 8 patients with complicated CD (3 with ulcerative jejunoileitis, 2 with refractory sprue, and 3 with enteropathy-associated T-cell lymphoma), and 14 control subjects.

Paneth cell numbers and proliferation did not differ in uncomplicated untreated and treated CD and control cases.

Paneth cell numbers and alpha-defensins are unchanged in the mucosa in uncomplicated CD.

[MeSH-major] Celiac Disease / pathology. Paneth Cells / pathology

[MeSH-minor] Adult. Aged. Cell Proliferation. Duodenum / pathology. Female. Humans. Intestinal Mucosa / pathology. Ki-67 Antigen / analysis. Male. Middle Aged. RNA, Messenger / metabolism. alpha-Defensins / analysis

Genetic Alliance. consumer health - Celiac Disease.

MedlinePlus Health Information. consumer health - Celiac Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18550468.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / alpha-Defensins; 0 / human neutrophil peptide 1

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

The M-protein is the major reference measure for response in multiple myeloma (MM) and its correct interpretation is key to clinical management.

The emergence of oligoclonal banding is recognized as a benign finding in the postautologous stem cell transplantation setting (ASCT) for MM but its significance during non-myeloablative therapy is unknown.

ASIPs were not associated with new clonal plasma cells or other lymphoproliferative processes, and molecular remissions were documented.

Analogous to the ASCT experience, ASIPs do not signal incipient disease progression, but rather herald robust response.

Genetic Alliance. consumer health - Multiple myeloma.

MedlinePlus Health Information. consumer health - Multiple Myeloma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. THALIDOMIDE .

Hazardous Substances Data Bank. Clarithromycin .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1994 Dec 15;84(12):4374-82 [7994052.001]

[Cites] Nephrol Dial Transplant. 1997 Jun;12(6):1199-203 [9198051.001]

[Cites] Blood. 1998 May 1;91(9):3518-23 [9558413.001]

[Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]

[Cites] J Clin Oncol. 1999 Jan;17(1):208-15 [10458235.001]

[Cites] Blood. 2005 Feb 15;105(4):1614-21 [15507523.001]

[Cites] Mayo Clin Proc. 2006 May;81(5):693-703 [16706268.001]

[Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]

[Cites] Nat Rev Immunol. 2006 Oct;6(10):741-50 [16977339.001]

[Cites] Nat Immunol. 2007 Apr;8(4):419-29 [17322888.001]

[Cites] Br J Haematol. 2004 Aug;126(3):348-54 [15257706.001]

[Cites] Blood. 2003 Sep 1;102(5):1927-9 [12738666.001]

[Cites] Leuk Lymphoma. 2002 Sep;43(9):1777-82 [12685831.001]

[Cites] J Clin Oncol. 2000 Jun;18(11):2273-81 [10829048.001]

[Cites] Bone Marrow Transplant. 2000 Apr;25(7):723-8 [10745257.001]

[Cites] Clin Chem. 1991 Aug;37(8):1334-7 [1907894.001]

[Cites] Blood. 1989 Dec;74(8):2764-8 [2819246.001]

[Cites] Blood. 2008 Feb 1;111(3):1101-9 [17989313.001]

[Cites] Blood. 1993 Jun 1;81(11):3153-7 [8499649.001]

(PMID = 18950461.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / K23 CA109260; United States / NCI NIH HHS / CA / K23 CA109260-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Immunoglobulins; 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide; H1250JIK0A / Clarithromycin

[Other-IDs] NLM/ NIHMS453628; NLM/ PMC3626496

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.

BACKGROUND: Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.

METHODS: Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T-cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7-institution, Phase II trial and treated with gemcitabine.

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / toxicity. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy

[MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16216001.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses.

Human T cell leukemia virus type 1 (HTLV-1) is a lymphotropic retrovirus whose cell-to-cell transmission requires cell contacts.

HTLV-1-infected T lymphocytes form 'virological synapses', but the mechanism of HTLV-1 transmission remains poorly understood.

We show here that HTLV-1-infected T lymphocytes transiently store viral particles as carbohydrate-rich extracellular assemblies that are held together and attached to the cell surface by virally-induced extracellular matrix components, including collagen and agrin, and cellular linker proteins, such as tetherin and galectin-3.

Extracellular viral assemblies rapidly adhere to other cells upon cell contact, allowing virus spread and infection of target cells.

Their removal strongly reduces the ability of HTLV-1-producing cells to infect target cells.

Our findings unveil a novel virus transmission mechanism based on the generation of extracellular viral particle assemblies whose structure, composition and function resemble those of bacterial biofilms.

HTLV-1 biofilm-like structures represent a major route for virus transmission from cell to cell.

[MeSH-major] CD4-Positive T-Lymphocytes / virology. Extracellular Matrix / virology. HTLV-I Infections / transmission. Human T-lymphotropic virus 1 / physiology

[MeSH-minor] Biofilms. Concanavalin A. Gene Products, env / metabolism. Humans. Microscopy, Electron, Transmission. Virus Assembly / physiology. Virus Attachment. Virus Internalization

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Nat Med. 2010 Jan;16(1):25-7 [20057417.001]

(PMID = 20023636.001).

[ISSN] 1546-170X

[Journal-full-title] Nature medicine

[ISO-abbreviation] Nat. Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Gene Products, env; 11028-71-0 / Concanavalin A

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HTLV-1 Tax-mediated TAK1 activation involves TAB2 adapter protein.

Human T cell leukemia virus type 1 (HTLV-1) Tax is an oncoprotein that plays a crucial role in the proliferation and transformation of HTLV-1-infected T lymphocytes.

[MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / metabolism. MAP Kinase Kinase Kinases / metabolism

[MeSH-minor] Binding Sites. Cell Line. Humans. NF-kappa B / metabolism. Ubiquitin-Protein Ligases / metabolism

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17986383.001).

[ISSN] 1090-2104

[Journal-full-title] Biochemical and biophysical research communications

[ISO-abbreviation] Biochem. Biophys. Res. Commun.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / TAB2 protein, human; 0 / tax protein, Human T-lymphotrophic virus 1; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP kinase kinase kinase 7; EC 6.3.2.19 / Ubiquitin-Protein Ligases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regulatory T-cell function of adult T-cell leukemia/lymphoma cells.

Adult T-cell leukemia/lymphoma (ATLL) patients are highly immunocompromised, but the underlying mechanism responsible for this state remains obscure.

Recent studies demonstrated that FOXP3, which is a master control gene of naturally occurring regulatory T (Treg) cells, is expressed in the tumor cells from a subset of patients with ATLL.

Since most ATLL cells express both CD4 and CD25, these tumors might originate from CD4(+)CD25(+)FOXP3(+) Treg cells, based on their phenotypic characteristics.

However, whether ATLL cells actually function as Treg cells has not yet been clearly demonstrated.

Here, we show that ATLL cells from a subset of patients are not only hypo-responsive to T-cell receptor-mediated activation, but also suppress the proliferation of autologous CD4(+) non-ATLL cells.

Furthermore, ATLL cells from this subset of patients secrete only small amounts of IFN-gamma, and suppress IFN-gamma production by autologous CD4(+) non-ATLL cells.

These are the first data showing that ATLL cells from a subset of patients function as Treg cells in an autologous setting.

The present study provides novel insights into understanding the immunopathogenesis of ATLL, i.e., how HTLV-1-infected cells can survive in the face of host immune responses.

It also adds to our understanding of ATLL patients' severely immunocompromised state.

[MeSH-major] Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes, Regulatory / physiology

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17278106.001).

[ISSN] 0020-7136

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00355472

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CCR4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / Receptors, CCR4; 0 / Receptors, Chemokine; 82115-62-6 / Interferon-gamma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.

The chromosomal translocation t(7;9) in human T-cell acute lymphoblastic leukaemia (T-ALL) results in deregulated expression of a truncated, activated form of Notch 1 (TAN1) under the control of the T-cell receptor-beta (TCRB) locus.

Although TAN1 efficiently induces T-ALL in mouse models, t(7;9) is present in less than 1% of human T-ALL cases.

The recent discovery of novel activating mutations in NOTCH1 in more than 50% of human T-ALL samples has made it clear that Notch 1 is far more important in human T-ALL pathogenesis than previously suspected.

[MeSH-major] Gene Expression Regulation, Leukemic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Receptor, Notch1 / metabolism

COS Scholar Universe. author profiles.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16612405.001).

[ISSN] 1474-175X

[Journal-full-title] Nature reviews. Cancer

[ISO-abbreviation] Nat. Rev. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1

[Number-of-references] 175

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.

OBJECTIVES: p53 mutations and high protein expression are associated with adverse prognosis in several lymphoma subtypes.

Matrix metalloproteinase-9 (MMP-9) has also been found to correlate with poor survival in all lymphomas studied.

The data concerning the clinical role of protein expression of p53 or gelatinases and their inhibitors in follicular lymphoma are rare.

The purpose of this study was to evaluate the prognostic and clinical implications of the immunoreactive proteins p53, MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and TIMP-2 in follicular lymphoma.

METHODS: The material consisted of 67 patients with primarily non-transformed follicular lymphoma.

CONCLUSIONS: In this study, p53 over-expression predicted both transformation to diffuse large B-cell lymphoma and poorer overall and cause-specific survival of patients with follicular lymphoma.

[MeSH-major] Gene Expression Regulation, Leukemic. Lymphoma, Follicular / metabolism. Matrix Metalloproteinase 9 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

[MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunochemistry. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis

Genetic Alliance. consumer health - Follicular Lymphoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18616513.001).

[ISSN] 1600-0609

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Denmark

[Chemical-registry-number] 0 / TP53 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tumor Suppressor Protein p53; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature.

Advances in immunophenotypic profiling now permit characterization of natural killer/T-cell (NK/T-cell) lymphoma as distinct from other extranodal T- and B-cell Non-Hodgkin's lymphomas.

NK/T-cell lymphoma presents most commonly in the nasal cavity.

Disease progression to the central nervous system (CNS) is a rare phenomenon.

We present here, to our knowledge, the first immunophenotypically-confirmed case of direct extension of nasal NK/T-cell lymphoma to the brain.

In addition, we review the literature with respect to NK/T-cell lymphoma metastasis to the CNS.

The overall prevalence of NK/T-cell lymphoma CNS metastasis is less than 3%.

[MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / pathology. Nose Neoplasms / immunology. Nose Neoplasms / pathology

[MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Antigens, CD3 / immunology. Antigens, CD4 / immunology. Antigens, CD56 / immunology. Craniotomy. Fatal Outcome. Follow-Up Studies. Humans. Immunophenotyping. Magnetic Resonance Imaging. Male. Pseudomonas aeruginosa / drug effects. Pseudomonas aeruginosa / isolation & purification. Staphylococcus aureus / drug effects. Staphylococcus aureus / isolation & purification. Time Factors

MedlinePlus Health Information. consumer health - Nasal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]

[Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]

[Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]

[Cites] Am J Surg Pathol. 1999 Nov;23(11):1356-69 [10555004.001]

[Cites] Am J Hematol. 1999 Feb;60(2):161-3 [9929112.001]

[Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]

[Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):797-802 [2004957.001]

[Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]

[Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]

[Cites] Leuk Lymphoma. 2000 Sep;39(1-2):139-44 [10975392.001]

[Cites] Clin Lab Haematol. 2000 Aug;22(4):215-20 [11012633.001]

[Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]

[Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1297-303 [11911411.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]

[Cites] Acta Oncol. 2003;42(7):779-83 [14690165.001]

[Cites] Am J Ophthalmol. 2002 Sep;134(3):406-10 [12208253.001]

[Cites] Curr Opin Oncol. 2003 Sep;15(5):353-62 [12960516.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1228-33 [11728681.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2001;:259-81 [11722988.001]

[Cites] Histopathology. 1995 Aug;27(2):139-48 [8835262.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]

[Cites] Med Oncol. 2003;20(1):13-7 [12665679.001]

(PMID = 16283442.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD56

[Number-of-references] 24

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.

Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results.

Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression.

Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. METHYLPREDNISOLONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15692599.001).

[ISSN] 1466-4860

[Journal-full-title] The hematology journal : the official journal of the European Haematology Association

[ISO-abbreviation] Hematol. J.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] T-cell lymphoblastic lymphoma presenting as an intra-muscular mass.

[MeSH-major] Fibula / pathology. Lymphoma, T-Cell, Peripheral / diagnosis. Magnetic Resonance Imaging. Muscle, Skeletal / pathology. Tibia / pathology

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Leukemic Infiltration. Male. Positron-Emission Tomography. Testis / pathology

Genetic Alliance. consumer health - Lymphoblastic lymphoma.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16445824.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aggressive NK cell leukaemia after splenectomy: association with CD95-resistant memory T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome.

We describe a 44-yr-old Japanese woman with persistent polyclonal T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome (HPS).

T cells bearing alphabeta T-cell receptors (TCR) expressed increased amounts of CD95 and of CD45RO, which are phenotypically memory T cells.

Aggressive natural killer cell leukaemia (ANKL) without an association with Epstein-Barr virus was detected 1 month after therapeutic splenectomy that followed 3 yr of immunosuppressive therapy against HPS.

The immunophenotype of these leukaemia cells was CD56, CD16(dim), CD7, CD45RA and they expressed some CD2, CD8 and HLA-DR.

Latent NK-cell malignancy seemed to cause the CD95-resistant memory T-cell proliferation and splenectomy resulted in overt ANKL progression.

There should be careful consideration of the risks versus benefits of splenectomy in HPS, in light of the possibility of fatal leukaemia/lymphoma progression.

[MeSH-major] Antigens, CD95 / physiology. Killer Cells, Natural / immunology. Leukemia / immunology. Leukemia / therapy. Lymphohistiocytosis, Hemophagocytic / immunology. Lymphohistiocytosis, Hemophagocytic / therapy. Splenectomy / adverse effects

[MeSH-minor] Adult. Cell Proliferation. Chromosome Aberrations. Disease Progression. Fatal Outcome. Female. Flow Cytometry. Follow-Up Studies. Humans. Immunophenotyping. Immunosuppressive Agents / therapeutic use. Karyotyping. Risk Factors

MedlinePlus Health Information. consumer health - Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18510705.001).

[ISSN] 1600-0609

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Antigens, CD95; 0 / Immunosuppressive Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.

Late-onset neutropenia, i.e. an absolute neutrophil count of <1.5 x 10(9)/l, may follow 4 weeks or more after therapy with rituximab for lymphoma.

In a retrospective study of 113 consecutive lymphoma patients treated with rituximab, with or without chemotherapy, we found eight patients (7%) with late-onset neutropenia (LON).

Four of the eight patients underwent stem cell transplantation.

In four subsequently identified patients with severe LON, a maturation arrest at the (pro)myelocyte stage was observed in the bone marrow, similar to that found in severe congenital neutropenia or Kostmann disease.

[MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Differentiation / drug effects. DNA Mutational Analysis. Female. Humans. Lymphoma / drug therapy. Male. Middle Aged. Proteins / genetics. Rituximab. Time

Hazardous Substances Data Bank. RITUXIMAB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Hematol. 2002 Apr;39(2):113-20 [11957194.001]

[Cites] Eur J Haematol Suppl. 2007 Jan;(67):5-14 [17206982.001]

[Cites] Eur J Haematol Suppl. 1996;60:93-7 [8987249.001]

[Cites] Haematologica. 2007 Feb;92(2):e20-3 [17405749.001]

[Cites] Int J Hematol. 2006 Oct;84(3):242-7 [17050199.001]

[Cites] Biol Blood Marrow Transplant. 2000;6(6):628-32 [11128813.001]

[Cites] Acta Paediatr. 2007 Jun;96(6):813-9 [17537008.001]

[Cites] Ann Pharmacother. 2005 Dec;39(12):2091-5 [16249269.001]

[Cites] Autoimmun Rev. 2006 Jan;5(1):18-24 [16338207.001]

[Cites] Curr Drug Metab. 2006 Apr;7(3):219-29 [16611018.001]

[Cites] Blood. 2005 Aug 1;106(3):795-802 [15718416.001]

[Cites] Br J Haematol. 2003 Jun;121(6):913-8 [12786803.001]

[Cites] J Immunol. 2005 Jul 15;175(2):1232-8 [16002727.001]

[Cites] Haematologica. 2004 Mar;89(3):361-3 [15020279.001]

[Cites] Acta Paediatr. 2006 Dec;95(12):1526-32 [17129957.001]

[Cites] Leuk Lymphoma. 2006 Jun;47(6):1013-7 [16840190.001]

[Cites] Leuk Res. 2002 Jun;26(6):597-600 [12007508.001]

[Cites] Bull Cancer. 2007 Feb;94(2):198-202 [17337389.001]

[Cites] Cancer Treat Rev. 2005 Oct;31(6):456-73 [16054760.001]

[Cites] Nature. 1996 Aug 15;382(6592):635-8 [8757135.001]

[Cites] Semin Hematol. 2006 Jul;43(3):189-95 [16822461.001]

[Cites] Blood. 2004 May 1;103(9):3355-61 [14764541.001]

[Cites] Bone Marrow Transplant. 2004 May;33(9):921-3 [15034544.001]

[Cites] Nat Genet. 2007 Jan;39(1):86-92 [17187068.001]

[Cites] Br J Haematol. 2005 Apr;129(2):275-8 [15813856.001]

[Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]

[Cites] N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 [12826650.001]

(PMID = 18278570.001).

[ISSN] 1357-0560

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HAX1 protein, human; 0 / Proteins; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.

BACKGROUND: Data assessing the role of positron emission tomography (PET)/computed tomography (CT) imaging in lymphoma staging is still being accumulated and current staging is based primarily on CT.

This study aims to compare the value of PET/CT over conventional CT and bone marrow biopsy (BMB) in the initial evaluation of patients with lymphoma.

RESULTS: Among the 122 patients, 101 had non-Hodgkin's lymphoma (NHL) and 21 had Hodgkin's lymphoma (HL).

Compared with conventional CT, PET/CT upstaged 21 (17%) cases [B-cell non-Hodgkin's lymphoma (B-NHL), 12; T-cell non-Hodgkin's lymphoma (T-NHL), 3; HL, 6].

A maximum FDG uptake of >10 standardized uptake value (SUV) seems to significantly correlate with an aggressive B-cell lineage (odds ratio 2.47, 95% confidence interval 2.23-2.70).

In HL, our data show that PET scan and marrow results agreed in 19 of the cases (90%), being concordantly negative in 18 cases and concordantly positive in one, giving a negative predictive value (NPV) of 100%, sensitivity of 100% and specificity of 90%.

In patients with aggressive B-NHL, BMB and PET/CT agreed in 58 patients (92%) and disagreed in five (8%), while the corresponding rates in indolent B-cell lymphoma were 14 (67%) and seven patients (33%), respectively.

MedlinePlus Health Information. consumer health - CT Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19474116.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells.

We have recently shown constitutive IkappaB kinase (IKK) activation and aberrant p52 expression in adult T cell leukemia (ATL) cells that do not express human T cell leukemia virus type I (HTLV-I) Tax, but the mechanism of IKK activation in these cells has remained unknown.

Here, we demonstrate distinct regulation of IKK activity in ATL and HTLV-I-transformed T cells in response to protein synthesis inhibition or arsenite treatment.

Protein synthesis inhibition for 4 h by cycloheximide (CHX) barely affects IKK activity in Tax-positive HTLV-I-transformed cells, while it diminishes IKK activity in Tax-negative ATL cells.

Treatment of ATL cells with a proteasome inhibitor MG132 prior to protein synthesis inhibition reverses the inhibitory effect of CHX, and MG132 alone greatly enhances IKK activity.

In addition, treatment of HTLV-I-transformed cells with arsenite for 1 h results in down-regulation of IKK activity without affecting Tax expression, while 8 h of arsenite treatment does not impair IKK activity in ATL cells.

These results indicate that a labile protein sensitive to proteasome-dependent degradation governs IKK activation in ATL cells, and suggest a molecular mechanism of IKK activation in ATL cells distinct from that in HTLV-I-transformed T cells.

[MeSH-major] Cell Transformation, Viral / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. Protein-Serine-Threonine Kinases / metabolism

[MeSH-minor] Arsenites / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Cycloheximide / antagonists & inhibitors. Cycloheximide / pharmacology. Enzyme Inhibitors / pharmacology. Human T-lymphotropic virus 1 / physiology. Humans. I-kappa B Kinase. Leupeptins / pharmacology. Proteasome Endopeptidase Complex / metabolism. Protein Synthesis Inhibitors / pharmacology. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism

Hazardous Substances Data Bank. CYCLOHEXIMIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15878527.001).

[ISSN] 0014-4827

[Journal-full-title] Experimental cell research

[ISO-abbreviation] Exp. Cell Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenites; 0 / Enzyme Inhibitors; 0 / Leupeptins; 0 / Protein Synthesis Inhibitors; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 98600C0908 / Cycloheximide; EC 2.7.1.- / IKBKE protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.10 / CHUK protein, human; EC 2.7.11.10 / I-kappa B Kinase; EC 2.7.11.10 / IKBKB protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex; N5509X556J / arsenite

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Extranodal T/NK-cell lymphoma, nasal type: a case report and review of the literature].

[Transliterated title] Linfoma T/NK extraganglionar tipo nasal: caso clínico y revisión de la literatura.

Extranodal T/NK-cell lymphoma, nasal type: a case report and review of the literature.

Extranodal NK/T-cell lymphoma, nasal type, is an extranodal lymphoma, usually with an NK-cell phenotype and EBV positive, with a broad morphologic spectrum, frequent necrosis and angioinvasion, and most commonly presenting in the midfacial region, but also in other extranodal sites.

The diagnosis of the case was Extranodal T/NK-cell lymphoma, nasal type.

There was not disseminated disease in the extent studies.

With the diagnosis of localized extranodal T/NK-cell lymphoma and reactive thrombocytosis, the patient was treated with chemotherapy and sequential radiotherapy, followed by bone marrow transplantation.

[MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology

[MeSH-minor] Adult. Humans. Immunophenotyping. Male

MedlinePlus Health Information. consumer health - Nasal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16454602.001).

[ISSN] 0212-7199

[Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)

[ISO-abbreviation] An Med Interna

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] Spain

[Number-of-references] 16

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genital herpes masquerading as a cutaneous T-cell lymphoma: a report of two cases.

Genital herpes simplex virus (HSV) infection is usually a straightforward clinical diagnosis, rarely requiring histological confirmation.

We report two cases of immunosuppressed patients in which the clinical and pathological features were initially suspicious for cutaneous lymphoma with a T-cell clone detected in one case.

A diagnosis of HSV infection was eventually made on the basis of histological features and confirmed with immunohistochemistry.

[MeSH-major] Herpes Genitalis / pathology. Immunocompromised Host. Lymphoma, T-Cell, Cutaneous / pathology

[MeSH-minor] Adult. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Male

Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

MedlinePlus Health Information. consumer health - Genital Herpes.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18422691.001).

[ISSN] 1600-0560

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Denmark

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis.

PURPOSE: We aimed to describe computed tomography (CT) findings in patients with peritoneal, omental and mesenteric lymphoma involvement.

MATERIALS AND METHODS: We searched our archive retrospectively to find out patients with peritoneal, omental and mesenteric lymphoma involvement.

We found 16 patients with non-Hodgkin lymphoma meeting these criteria.

CT studies of these patients were reevaluated for the presence of peritoneal involvement, ascites, omental mass, organomegaly, retroperitoneal lymphadenopathy, bowel wall thickening and other associated findings.

RESULTS: There were 14 males and 2 females with peritoneal and/or mesenteric and omental lymphoma involvement.

Subgroups of non-Hodgkin lymphoma were diffuse large B-cell lymphoma (n=11), small cell lymphocytic lymphoma (n=2), small cleaved cell lymphoma (n=1), T-cell lymphoma (n=1) and Burkitt's lymphoma (n=1).

CONCLUSION: Peritoneal involvement can be seen in many subtypes of lymphoma and most frequently in diffuse large B-cell lymphoma.

Peritoneal lymphomatosis can mimic peritoneal carcinomatosis and should be included in the differential diagnosis list in patients with ascites, hepatosplenic lesions and unidentified cause of peritoneal thickening on CT in a male patient.

[MeSH-major] Lymphoma / radiography. Mesentery / radiography. Omentum / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18513906.001).

[ISSN] 1872-7727

[Journal-full-title] European journal of radiology

[ISO-abbreviation] Eur J Radiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Ireland

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Midline destructive lesions (MDLs) of the nose are a diagnostic dilemma due to an extensive differential diagnosis and vague presenting signs and symptoms.

Laboratory tests included complete blood count, basic metabolic panel, erythrocyte sedimentation rate, angiotensin-converting enzyme, antineutrophil antibodies, rheumatoid factor, anti-Ro and anti-La antibodies, Epstein-Barr virus antibodies, coccidiomycosis serology, HIV antibodies, fluorescent treponemal antibody absorption, classic antineutrophil cytoplasmic antibodies, perinuclear antineutrophil cytoplasmic antibody, proteinase 3, and myeloperoxidase.

Two patients were diagnosed with natural killer/T-cell lymphoma, 2 were diagnosed with Wegener's granulomatosis, and 4 remained idiopathic, despite the extensive workup.

CONCLUSIONS: The diagnosis of MDLs remains difficult but is aided by a systematic approach and familiarity with multiple diagnostic techniques.

It is imperative to take multiple tissue specimens from various sites, send them fresh, and communicate suspicion of lymphoma.

[MeSH-major] Granuloma, Lethal Midline / diagnosis

[MeSH-minor] Adult. Algorithms. Diagnosis, Differential. Female. Granulomatosis with Polyangiitis / diagnosis. Humans. Lymphoma, T-Cell / diagnosis. Male. Middle Aged

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.

(PMID = 20015726.001).

[ISSN] 1532-818X

[Journal-full-title] American journal of otolaryngology

[ISO-abbreviation] Am J Otolaryngol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 25

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.

Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I), which induces nuclear factor-kappaB (NF-kappaB), a molecule central to the ensuing neoplasia.

The NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) has been shown to inhibit NF-kappaB activation in Tax-expressing HTLV-I-infected cells.

In this study, we used NOD/SCID beta2-microglobulin(null) mice to show that intraperitoneal inoculation with Tax-deficient ATL cell lines caused rapid death, whereas DHMEQ-treated mice survived.

Furthermore, DHMEQ treatment after subcutaneous inoculation inhibited the growth of transplanted ATL cells.

These results demonstrate that DHMEQ has therapeutic efficacy on ATL cells, regardless of Tax expression.

[MeSH-major] Benzamides / pharmacology. Cyclohexanones / pharmacology. Gene Products, tax / deficiency. Leukemia, T-Cell / prevention & control. Xenograft Model Antitumor Assays / methods

[MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cell Line, Tumor. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / metabolism. Humans. Mice. Mice, Inbred NOD. Mice, Knockout. Mice, SCID. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Burden. beta 2-Microglobulin / genetics. beta 2-Microglobulin / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17764832.001).

[ISSN] 0304-3835

[Journal-full-title] Cancer letters

[ISO-abbreviation] Cancer Lett.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / Benzamides; 0 / Cyclohexanones; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / beta 2-Microglobulin; 0 / dehydroxymethylepoxyquinomicin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.

Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for adult T cell leukemia/lymphoma (ATLL), but shows high mortality.

We evaluated the feasibility of reduced-intensity transplantation using fludarabine and busulfan, with particular focus on the clinical impact of antithymocyte globulin (ATG) in the conditioning regimen.

Fourteen elderly patients with aggressive ATLL were enrolled in the current study without ATG, and were compared to those in 15 patients who were treated similarly, but with ATG, in our previous study.

Analysis of combined data from both our current and previous studies disclosed that grade I-II acute GVHD was the only factor that favorably affected OS and PFS.

These data suggested the presence of a graft-versus-ATLL effect and the feasibility of a transplant procedure without ATG in elderly ATLL patients, but could not demonstrate the clinical benefit of incorporating ATG.

[MeSH-major] Antilymphocyte Serum / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / surgery. Transplantation Conditioning / methods

[MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Human T-lymphotropic virus 1 / isolation & purification. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Proviruses / isolation & purification. Survival Analysis. T-Lymphocytes. Transplantation, Homologous. Treatment Outcome

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18489996.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Imaging features of primary bone lymphoma and its histopathology].

OBJECTIVE: To study the imaging features of primary bone of the lymphoma PLB on X-ray, CT and magnetic resonance imaging (MRI).

Histological examination identified B-cell lymphoma in 5 cases and T-cell lymphoma in 4 cases.

[MeSH-major] Bone Neoplasms / radiography. Lymphoma / radiography. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

[MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Retrospective Studies

MedlinePlus Health Information. consumer health - Bone Cancer.

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - Lymphoma.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17355937.001).

[ISSN] 1673-4254

[Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University

[ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.

The gene NPM1 that encodes for nucleophosmin (NPM1) is translocated or mutated in various lymphomas and leukemias, forming fusion proteins (NPM-ALK, NPM-RARalpha, NPM-MLF1) or NPM mutant products.

Here, we review the structure and functions of NPM, as well as the biological, clinical and pathological features of human hematologic malignancies with NPM1 gene alterations.

NPM-ALK indentifies a new category of T/Null lymphomas with distinctive molecular and clinico-pathological features, that is going to be included as a novel disease entity (ALK+ anaplastic large cell lymphoma) in the new WHO classification of lymphoid neoplasms.

NPM1 mutations occur specifically in about 30% of adult de novo AML and cause aberrant cytoplasmic expression of NPM (hence the term NPMc+ AML).

NPMc+ AML associates with normal karyotpe, and shows wide morphological spectrum, multilineage involvement, a unique gene expression signature, a high frequency of FLT3-internal tandem duplications, and distinctive clinical and prognostic features.

The availability of specific antibodies and molecular techniques for the detection of NPM1 gene alterations has an enormous impact in the biological study diagnosis, prognostic stratification, and monitoring of minimal residual disease of various lymphomas and leukemias.

[MeSH-major] Leukemia, Myeloid / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Nuclear Proteins / physiology

[MeSH-minor] Acute Disease. Adult. Age of Onset. Alternative Splicing. Amino Acid Motifs. Biological Transport. Cell Nucleolus / metabolism. Cell Nucleus / metabolism. Child. Chromosomes, Human, Pair 5 / genetics. Cytoplasm / metabolism. Humans. Karyotyping. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / physiology. Prognosis. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / physiology. Ribosomes / metabolism. Structure-Activity Relationship. Translocation, Genetic. Treatment Outcome

Genetics Home Reference. consumer health - NPM1 gene.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17488663.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Italy

[Chemical-registry-number] 0 / NPM-MLF1 protein, human; 0 / NPM-RARalpha protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases

[Number-of-references] 166

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.

Also reviewed are nelarabine's clinical efficacy in T-ALL, T-LBL, and other hematologic malignancies; its toxicity profile, dosage, and administration; and areas of ongoing and future research.

Nelarabine has activity in T-cell malignancies, as evaluated in 2 Phase I and 5 Phase II studies.

Among patients with central nervous system-positive T-ALL or T-cell non-Hodgkins lymphoma (T-NHL) (n = 21), 33% had an objective response (5 CR and 2 PR); among patients with T-ALL or T-NHL with extramedullary relapse (n = 22), 14% had a PR.

CALGB 19801 included 39 adult patients with T-cell malignancies, of whom 7 (18%) had a CR and an additional 2 (5%) had a CR without full hematologic recovery.

Objective response rates in Phase II clinical trials of nelarabine have ranged from 11% to 60%.

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Arabinonucleosides / therapeutic use. Hematologic Neoplasms / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Purine Nucleosides / therapeutic use

SciCrunch. DrugBank: Data: Chemical .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18035189.001).

[ISSN] 0149-2918

[Journal-full-title] Clinical therapeutics

[ISO-abbreviation] Clin Ther

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Arabinonucleosides; 0 / Purine Nucleosides; 60158CV180 / nelarabine

[Number-of-references] 29

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Nasal NK/T cell lymphoma: a report of 11 cases].

OBJECTIVE: To investigate the clinical diagnosis consideration of nasal NK/T cell lymphoma.

METHOD: Reviewing the clinical data of 11 patients with nasal NK/T cell lymphoma between 1992 to 2003.

CONCLUSION: Nasal NK/T cell lymphoma is easily misdiagnosed.

The right diagnosis can be built with clinical, pathological and imaging examination.

[MeSH-major] Diagnostic Errors. Lymphoma, Extranodal NK-T-Cell. Nose Neoplasms

[MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

MedlinePlus Health Information. consumer health - Nasal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16248460.001).

[Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology

[ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].

OBJECTIVE: To study the morphologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma (AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.

Cases of peripheral T-cell lymphoma, unspecified, extranodal NK/T-cell lymphoma, nasal-type, enteropathy-type T-cell lymphoma, anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma and reactive lymphoid proliferation were selected as controls.

RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-cell lymphoma, unspecified were negative.

As for bcl-6 staining, although the highest percentage of bcl-6-positive cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-cell lymphoma, unspecified and lymphoid reaction.

Two of the cases, which contained obvious germinal centers, had the follicular dendritic cell meshwork extending beyond the lymphoid follicles.

[MeSH-major] Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism

[MeSH-minor] Adult. Aged. Female. Humans. Immunophenotyping. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-6 / metabolism. Receptors, Complement 3d / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19575853.001).

[ISSN] 0529-5807

[Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology

[ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.

Human respiratory syncytial virus (RSV) is the most important agent of serious pediatric respiratory tract disease worldwide.

One of the main characteristics of RSV is that it readily reinfects and causes disease throughout life without the need for significant antigenic change.

The virus encodes nonstructural protein 1 (NS1) and NS2, which are known to suppress type I interferon (IFN) production and signaling.

In the present study, we monitored the maturation of human monocyte-derived myeloid dendritic cells (DC) following inoculation with recombinant RSVs bearing deletions of the NS1 and/or NS2 proteins and expressing enhanced green fluorescent protein.

Deletion of the NS1 protein resulted in increased expression of cell surface markers of DC maturation and an increase in the expression of multiple cytokines and chemokines.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Respir Cell Mol Biol. 2004 Jun;30(6):893-900 [14722224.001]

[Cites] J Immunol. 2004 Sep 1;173(5):3408-17 [15322205.001]

[Cites] N Engl J Med. 1979 Mar 8;300(10):530-4 [763253.001]

[Cites] Nature. 1980 Apr 10;284(5756):555-6 [6245367.001]

[Cites] Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402 [3457562.001]

[Cites] Am J Pathol. 1990 Mar;136(3):593-608 [2156431.001]

[Cites] Vaccine. 1990 Oct;8(5):497-502 [2251875.001]

[Cites] J Infect Dis. 1991 Apr;163(4):693-8 [2010624.001]

[Cites] J Immunol. 1991 Dec 15;147(12):4307-12 [1753101.001]

[Cites] J Immunol. 1992 Jul 15;149(2):735-42 [1378080.001]

[Cites] Biochim Biophys Acta. 1994 Apr 5;1197(1):63-93 [8155692.001]

[Cites] J Immunol. 1995 Apr 15;154(8):3821-35 [7706722.001]

[Cites] Immunology. 1995 Jul;85(3):364-72 [7558123.001]

[Cites] J Exp Med. 1995 Nov 1;182(5):1545-56 [7595224.001]

[Cites] J Clin Invest. 1995 Nov;96(5):2445-53 [7593633.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11563-7 [8524804.001]

[Cites] J Infect Dis. 1996 Sep;174(3):456-62 [8769600.001]

[Cites] J Infect Dis. 1997 Mar;175(3):497-504 [9041319.001]

[Cites] J Immunol. 2007 Jul 1;179(1):673-81 [17579090.001]

[Cites] J Biol Chem. 2007 Jul 13;282(28):20053-7 [17502368.001]

[Cites] Immunity. 2007 Aug;27(2):240-52 [17723216.001]

[Cites] Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):425-33 [17683972.001]

[Cites] Vaccine. 2007 Oct 16;25(42):7372-8 [17868959.001]

[Cites] Viral Immunol. 2007 Dec;20(4):531-40 [18158727.001]

[Cites] J Virol. 2008 Mar;82(5):2040-55 [17928346.001]

[Cites] J Gen Virol. 2005 Jun;86(Pt 6):1645-57 [15914842.001]

[Cites] Blood. 2005 Jul 1;106(1):216-23 [15790784.001]

[Cites] J Virol. 2005 Jul;79(14):9315-9 [15994826.001]

[Cites] J Exp Med. 2005 Sep 5;202(5):637-50 [16129706.001]

[Cites] J Immunol. 2005 Nov 1;175(9):5904-11 [16237083.001]

[Cites] J Immunol. 2006 Feb 1;176(3):1600-8 [16424189.001]

[Cites] Blood. 2006 Feb 15;107(4):1528-36 [16239433.001]

[Cites] Am J Respir Cell Mol Biol. 2006 Mar;34(3):320-9 [16284360.001]

[Cites] Blood. 2006 Mar 15;107(6):2392-9 [16293598.001]

[Cites] J Virol. 2006 Apr;80(7):3416-27 [16537609.001]

[Cites] Int Arch Allergy Immunol. 2006;140(1):53-72 [16534219.001]

[Cites] J Virol. 2006 May;80(10):5032-40 [16641294.001]

[Cites] J Virol. 2006 Jun;80(12):5958-67 [16731934.001]

[Cites] J Leukoc Biol. 2006 Jun;79(6):1286-94 [16624932.001]

[Cites] J Virol. 2006 Jul;80(13):6295-304 [16775317.001]

[Cites] J Virol. 2006 Aug;80(16):8151-7 [16873271.001]

[Cites] Eur J Immunol. 2006 Jul;36(7):1827-36 [16783851.001]

[Cites] Immunity. 2006 Sep;25(3):373-81 [16979569.001]

[Cites] Blood. 2006 Dec 1;108(12):3792-800 [16917011.001]

[Cites] J Exp Med. 2007 Jan 22;204(1):171-80 [17190836.001]

[Cites] J Mol Biol. 2007 Feb 16;366(2):525-39 [17174979.001]

[Cites] J Virol. 2007 Feb;81(4):1786-95 [17151097.001]

[Cites] J Virol. 2007 Apr;81(7):3428-36 [17251292.001]

[Cites] Arch Dermatol Res. 2007 May;299(2):59-69 [17334966.001]

[Cites] Virology. 2007 Aug 15;365(1):144-56 [17459446.001]

[Cites] J Virol. 2003 Aug;77(15):8426-39 [12857912.001]

[Cites] J Virol. 2003 Aug;77(16):8661-8 [12885884.001]

[Cites] J Virol. 2003 Sep;77(17):9156-72 [12915532.001]

[Cites] J Virol. 2003 Oct;77(20):11201-11 [14512568.001]

[Cites] Virology. 2003 Nov 10;316(1):41-54 [14599789.001]

[Cites] J Infect Dis. 2003 Dec 1;188(11):1630-8 [14639532.001]

[Cites] J Virol. 2004 Apr;78(8):4363-9 [15047850.001]

[Cites] JAMA. 1999 Oct 20;282(15):1440-6 [10535434.001]

[Cites] Eur J Immunol. 1999 Nov;29(11):3596-602 [10556814.001]

[Cites] J Exp Med. 2000 May 15;191(10):1777-88 [10811870.001]

[Cites] J Virol. 2000 Aug;74(15):7127-36 [10888653.001]

[Cites] Virology. 2000 Jul 20;273(1):210-8 [10891423.001]

[Cites] J Virol. 2000 Oct;74(19):9317-21 [10982380.001]

[Cites] Eur J Immunol. 2000 Oct;30(10):2741-50 [11069053.001]

[Cites] Nat Immunol. 2000 Nov;1(5):398-401 [11062499.001]

[Cites] J Virol. 2001 Dec;75(24):12128-40 [11711604.001]

[Cites] Blood. 2002 Apr 15;99(8):2913-21 [11929782.001]

[Cites] Int Immunol. 2002 Apr;14(4):367-80 [11934873.001]

[Cites] Cancer Immunol Immunother. 2002 May;51(3):139-44 [11941452.001]

[Cites] J Virol. 2002 Oct;76(20):10109-21 [12239285.001]

[Cites] Biochem J. 2002 Oct 1;367(Pt 1):145-55 [12084011.001]

[Cites] J Immunol. 2003 Mar 15;170(6):2797-801 [12626527.001]

[Cites] J Infect Dis. 2003 Apr 1;187(7):1126-36 [12660927.001]

[Cites] Immunology. 2003 May;109(1):49-57 [12709017.001]

[Cites] Eur J Immunol. 2003 Jun;33(6):1677-85 [12778486.001]

[Cites] J Virol. 1997 Jul;71(7):4944-53 [9188557.001]

[Cites] Mamm Genome. 1997 Aug;8(8):581-2 [9250865.001]

[Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]

[Cites] J Immunol. 1998 May 1;160(9):4298-304 [9574532.001]

[Cites] J Virol. 1998 Jun;72(6):4756-64 [9573240.001]

[Cites] J Virol. 1999 Jan;73(1):466-73 [9847352.001]

[Cites] Cell Death Differ. 1999 Feb;6(2):99-104 [10200555.001]

[Cites] Science. 1999 Jun 11;284(5421):1835-7 [10364556.001]

[Cites] Nat Med. 1999 Aug;5(8):919-23 [10426316.001]

[Cites] Eur J Immunol. 1999 Sep;29(9):2769-78 [10508251.001]

[Cites] J Virol. 2005 May;79(9):5353-62 [15827150.001]

[Cites] J Virol. 2005 May;79(9):5507-15 [15827165.001]

[Cites] N Engl J Med. 2005 Apr 28;352(17):1749-59 [15858184.001]

[Cites] Leuk Lymphoma. 2004 Feb;45(2):257-64 [15101709.001]

(PMID = 18562519.001).

[ISSN] 1098-5514

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] ENG

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Annexin A5; 0 / Cytokines; 0 / Viral Nonstructural Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 3.4.22.- / Caspase 3

[Other-IDs] NLM/ PMC2519638

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?

The immune system has several mechanisms to fight against developing malignant cell clones in the host, one of them is the activated T-cell response.

Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's lymphoma (NHL) patients during the periods of polychemotherapy.

We suppose that investigation of CD3+/HLA-DR+ activated T cells might be a promising method to determine the prognostics of lymphoma patients.

[MeSH-major] Antigens, CD3 / immunology. HLA-DR Antigens / immunology. Lymphoma, Non-Hodgkin / diagnosis. T-Lymphocytes / immunology

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15626488.001).

[ISSN] 0165-2478

[Journal-full-title] Immunology letters

[ISO-abbreviation] Immunol. Lett.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antigens, CD3; 0 / HLA-DR Antigens

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [The expression and clinical significance of early differentiation antigens in acute leukemia].

OBJECTIVE: To evaluate the expression and clinical significance of early differentiation antigens of hematopoietic cells CD(34), CD(90) and CD(133) in acute leukemia (AL).

The expression of CD(133) antigen was highly correlated with CD(133) mRNA expression in both of the normal control donors and AL patients (r = 0.932, P < 0.01). (2) The positive rates of CD(34), CD(90) and CD(133) in all AL patients were 63.2%, 7.9% and 42.1%, respectively.

Positive expression of CD(133) in AML-M(4) was significantly higher than that in other AML subtypes (P < 0.01).

The positive rate of CD(34) in B-ALL was much higher than that in T-ALL (P < 0.05). (3) CD(133) expression in AML was significantly correlated with the expression of CD(34) and HLA-DR (P < 0.01). (4) The expression of CD(34), CD(90) and CD(133) was not associated with the clinical prognostic factors such as cytogenetic or molecular aberrations, initial peripheral blood WBC counts, lactate dehydrogenase level, multiple drug resistant expression and age. (5) There was a trend toward lower completely remission (CR) rate and overall survival rate in CD(34), CD(90) and CD(133) positive cases, but only CD(34)(+)/CD(133)(+) cases had significant lower CR rate than negative ones (P < 0.05).

CD(133)/CD(34) co-expression might provide adverse prognostic stratification of acute leukemia.

[MeSH-major] Antigens, CD34 / metabolism. Antigens, Thy-1 / metabolism. Glycoproteins / metabolism. Leukemia, Myeloid, Acute / metabolism. Peptides / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

[MeSH-minor] Adolescent. Adult. Aged. Antigens, CD. Child. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / genetics

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15769398.001).

[ISSN] 0578-1426

[Journal-full-title] Zhonghua nei ke za zhi

[ISO-abbreviation] Zhonghua Nei Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Thy-1; 0 / Glycoproteins; 0 / Peptides; 0 / RNA, Messenger

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pagetoid reticulosis (PR) is a low-grade primary cutaneous T-cell lymphoma that usually presents as a solitary, slowly enlarging erythematous or hyperkeratotic plaque on the distal areas of the extremities.

Histopathologically, it is characterized by a dense, band-like infiltrate of atypical lymphocytes with prominent epidermotropism within a hyperplastic epidermis, and immunophenotypic studies show in most cases, a CD4-positive T-helper phenotype for the neoplastic lymphocytes.

We describe an African man with a more than 20-year history of an acral lesion of PR, which was histopathologically characterized by lymphocyte immunophenotype consisting of CD8- and CD30-positive cells.

We discuss the differential diagnosis with other primary cutaneous lymphoproliferative disorders showing similar immunophenotype.

This case shows that CD30-positive PR should be included as a rare variant within the spectrum of CD30-positive primary cutaneous lymphoproliferative disorders.

As in other primary cutaneous CD30-positive lymphoproliferative processes, lesions of CD30-positive PR show an indolent course and a benign biological behavior.

[MeSH-major] Antigens, CD30 / metabolism. Lymphatic Diseases / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology. T-Lymphocytes, Cytotoxic / pathology

[MeSH-minor] Adult. Biomarkers / metabolism. Biopsy. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Humans. Immunophenotyping. Male

MedlinePlus Health Information. consumer health - Lymphatic Diseases.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17640236.001).

[ISSN] 0303-6987

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.

In this multicentric study we collected 27 cases of NUP214-ABL1-positive T-ALL.

An associated abnormality involving TLX1 or TLX3 was found in all investigated cases.

In addition, intrachromosomal amplification (small hsr) was identified either as the only change or in association with episomes in four cases and two T-ALL cell lines (PEER and ALL-SIL).

[MeSH-major] Gene Amplification. Leukemia-Lymphoma, Adult T-Cell / genetics. Oncogene Proteins, Fusion / genetics

[MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Child. Child, Preschool. Female. Homeodomain Proteins / genetics. Humans. Male. Middle Aged. Plasmids. Proto-Oncogene Proteins / genetics. Sex Factors. Treatment Outcome. Young Adult

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18923437.001).

[ISSN] 1476-5551

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / TLX3 protein, human; 143275-75-6 / TLX1 protein, human

[Investigator] Barin C; Berger R; Bilhou-Nabera C; Cabrol C; Callet-Bauchu E; Cornillet-Lefebvre P; Laï JL; Lefebvre C; Luquet I; Perot C; Radford-Weiss I; Speleman F; Cauwelier B; Talmant P; Terré C; Tigaud I; Van DenAkker J; Viguié F

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

After stimulation with anti-CD3 antibody in vitro, CD57(+) T cells showed a greater susceptibility to apoptosis than CD57(-)alphabetaT cell receptor (TCR)(+) T cells (regular alphabeta T cells).

CD57(+) T cells display a biased expansion of a few Vbeta T cell fractions in individuals, but such Vbeta T cells were not specifically susceptible to CD3-mediated apoptosis.

Although the CD3epsilon expression levels were similar in both T cell subsets, the CD3zeta level of CD57(+) T cells was significantly higher than that of regular T cells.

[MeSH-minor] Adult. Antibodies / pharmacology. Antigens, CD95 / analysis. Antigens, CD95 / immunology. Apoptosis / immunology. Caspase 3. Caspases / metabolism. Cells, Cultured. Fas Ligand Protein. Humans. Immunoglobulin epsilon-Chains / analysis. Immunoglobulin gamma-Chains / analysis. Inhibitor of Apoptosis Proteins. Membrane Glycoproteins / analysis. Membrane Glycoproteins / immunology. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / immunology. Neoplasm Proteins. Receptors, Antigen, T-Cell, alpha-beta / immunology. Reverse Transcriptase Polymerase Chain Reaction

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leuk Lymphoma. 1999 Nov;35(5-6):545-54 [10609792.001]

[Cites] Int Immunol. 1998 Dec;10(12):1837-45 [9885904.001]

[Cites] Immunol Rev. 2000 Apr;174:35-46 [10807505.001]

[Cites] Immunol Rev. 2000 Apr;174:135-49 [10807513.001]

[Cites] J Immunol. 2000 Jun 1;164(11):5652-8 [10820240.001]

[Cites] Eur J Immunol. 2000 Jul;30(7):1919-28 [10940881.001]

[Cites] Hepatology. 2000 Nov;32(5):962-9 [11050046.001]

[Cites] Hum Immunol. 2000 Sep;61(9):908-16 [11053634.001]

[Cites] Clin Cancer Res. 2001 Jan;7(1):74-80 [11205921.001]

[Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):947s-957s [11300496.001]

[Cites] J Immunol. 2001 Jun 1;166(11):6578-84 [11359810.001]

[Cites] Immunology. 2001 Jul;103(3):281-90 [11454057.001]

[Cites] Clin Exp Immunol. 2002 Jun;128(3):453-9 [12109440.001]

[Cites] Clin Exp Immunol. 2002 Oct;130(1):162-8 [12296868.001]

[Cites] J Immunol. 2002 Dec 1;169(11):6127-32 [12444115.001]

[Cites] Immunology. 2003 Feb;108(2):211-9 [12562330.001]

[Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]

[Cites] J Immunol. 2003 Aug 15;171(4):1901-8 [12902492.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10913-8 [12960397.001]

[Cites] J Immunol. 2003 Oct 15;171(8):4020-7 [14530322.001]

[Cites] J Immunol. 2004 Jun 1;172(11):6550-7 [15153469.001]

[Cites] Immunology. 2004 Sep;113(1):35-43 [15312134.001]

[Cites] J Immunol. 1981 Sep;127(3):1024-9 [6790607.001]

[Cites] J Immunol. 1983 Oct;131(4):1822-6 [6413578.001]

[Cites] Transplantation. 1985 Jan;39(1):25-9 [3880961.001]

[Cites] J Immunol. 1986 Oct 1;137(7):2180-9 [2944951.001]

[Cites] J Immunol. 1986 Nov 1;137(9):2808-13 [2944964.001]

[Cites] J Immunol. 1988 Dec 1;141(11):3791-7 [2903195.001]

[Cites] Annu Rev Cell Biol. 1990;6:403-31 [2275818.001]

[Cites] J Immunol. 1991 Aug 15;147(4):1214-21 [1831220.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1492-6 [1346934.001]

[Cites] Nature. 1992 Mar 26;356(6367):314-7 [1372394.001]

[Cites] Arthritis Rheum. 1993 May;36(5):608-12 [7683880.001]

[Cites] Curr Opin Immunol. 1993 Jun;5(3):324-33 [8347295.001]

[Cites] Int Rev Immunol. 1994;11(1):61-102 [8057045.001]

[Cites] Eur J Immunol. 1994 Nov;24(11):2882-8 [7525310.001]

[Cites] Nature. 1995 Feb 2;373(6513):438-41 [7530335.001]

[Cites] Nature. 1995 Feb 2;373(6513):441-4 [7530336.001]

[Cites] Nature. 1995 Feb 2;373(6513):444-8 [7530337.001]

[Cites] J Exp Med. 1995 Feb 1;181(2):781-6 [7530763.001]

[Cites] J Immunol. 1995 Apr 15;154(8):3806-13 [7706720.001]

[Cites] EMBO J. 1995 Mar 15;14(6):1129-35 [7536672.001]

[Cites] J Exp Med. 1995 May 1;181(5):1881-6 [7722462.001]

[Cites] J Immunol. 1995 Jun 1;154(11):6182-90 [7538544.001]

[Cites] Mech Ageing Dev. 1996 Jul 5;88(1-2):25-38 [8804091.001]

[Cites] Mech Ageing Dev. 1997 Mar;94(1-3):123-34 [9147365.001]

[Cites] Hepatology. 1997 Aug;26(2):301-9 [9252138.001]

[Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]

[Cites] J Clin Immunol. 1997 Sep;17(5):420-9 [9327342.001]

[Cites] J Immunol. 1998 Feb 15;160(4):1627-37 [9469419.001]

[Cites] Clin Exp Immunol. 1998 Feb;111(2):345-52 [9486402.001]

[Cites] Scand J Immunol. 1998 Mar;47(3):254-62 [9519864.001]

[Cites] Br J Haematol. 1998 Mar;100(4):784-92 [9531350.001]

[Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]

[Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]

[Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]

[Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]

(PMID = 15654825.001).

[ISSN] 0009-9104

[Journal-full-title] Clinical and experimental immunology

[ISO-abbreviation] Clin. Exp. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Antigens, CD57; 0 / Antigens, CD95; 0 / BIRC5 protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Immunoglobulin epsilon-Chains; 0 / Immunoglobulin gamma-Chains; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Antigen, T-Cell, alpha-beta; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases

[Other-IDs] NLM/ PMC1809296

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?

Acute and chronic graft-versus-host disease (GVHD) continue to be major limitations to successful hematopoietic stem cell transplantation.

Photopheresis is currently indicated and Food and Drug Administration-approved for the treatment of skin manifestations of cutaneous T-cell lymphoma, where the response rate has proved to be considerably high.

Extracorporeal photochemotherapy has been evaluated in small cohorts of patients with both acute and chronic GVHD.

In steroid-refractory acute GVHD of the skin and liver, the reported response rate is more than 60%, especially in patients with less severe forms of the disease.

All of these results indicate activity of extracorporeal photopheresis in acute and chronic GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies.

[MeSH-major] Graft vs Host Disease / therapy. Photopheresis

[MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Chronic Disease. Cohort Studies. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasms / complications. Neoplasms / mortality. Neoplasms / therapy. Remission Induction. Retrospective Studies

Genetic Alliance. consumer health - Chronic Graft versus Host Disease.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16399600.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Huge mass of cutaneous-type adult T-cell leukemia which responded to interferon gamma.

[MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17268135.001).

[ISSN] 1349-7235

[Journal-full-title] Internal medicine (Tokyo, Japan)

[ISO-abbreviation] Intern. Med.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 82115-62-6 / Interferon-gamma

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.

PURPOSE: The pathogenesis and clinical heterogeneity of gastric diffuse large B-cell lymphoma (DLBCL) are poorly understood.

We have comprehensively investigated the incidence and clinical significance of lymphoma-associated chromosomal translocations, particularly those involving the immunoglobulin heavy chain (IGH) gene locus, in a large series of gastric DLBCL.

EXPERIMENTAL DESIGN: One hundred forty-one cases of primary gastric DLBCL [58 with mucosa-associated lymphoid tissue (MALT) lymphoma and 83 without MALT lymphoma] were enrolled.

In positive cases, additional fluorescence in situ hybridization was done with appropriate probes for potential partner genes.

Cases were classified into germinal center B-cell-like (GCB) or non-GCB subgroups by immunophenotyping with CD10, BCL6, and MUM1.

RESULTS: Translocations involving IGH were detected in 36 (32%) of 111 cases; their partner genes included BCL6 (n = 10), c-MYC (n = 5), and FOXP1 (n = 3) but remained unknown in the remaining 18 cases. t(14;18)/IGH-BCL2, t(14;18)/IGH-MALT1, and t(1;14)/BCL10-IGH were not detected in any case. t(11;18)/API2-MALT1 was detected in none of the cases, except for one case of DLBCL with MALT lymphoma, which showed positive signals only in MALT lymphoma cells.

IGH-involved translocation was associated with younger age but not with any other clinicopathologic factors including GCB or non-GCB immunophenotypes.

[MeSH-major] Immunoglobulin Heavy Chains / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Stomach Neoplasms / genetics. Translocation, Genetic

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

Genetic Alliance. consumer health - Gastric Lymphoma.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

MedlinePlus Health Information. consumer health - Stomach Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18445693.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United Kingdom / Wellcome Trust / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Immunoglobulin Heavy Chains

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cerebral sinus thrombosis is a rare but severe complication during treatment for acute lymphoblastic leukaemia (ALL).

Hypertriglyceridemia has - albeit very rarely - also been associated with asparaginase therapy.

Here we describe a 15-year-old boy who presented with clinical symptoms and radiologic findings of a cerebral sinus thrombosis.

[MeSH-major] Antineoplastic Agents / toxicity. Antineoplastic Combined Chemotherapy Protocols / toxicity. Asparaginase / toxicity. Hypertriglyceridemia / chemically induced. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Polyethylene Glycols / toxicity. Sinus Thrombosis, Intracranial / chemically induced

MedlinePlus Health Information. consumer health - Triglycerides.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17405075.001).

[ISSN] 0300-8630

[Journal-full-title] Klinische Pädiatrie

[ISO-abbreviation] Klin Padiatr

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Heparin, Low-Molecular-Weight; 0 / Hypolipidemic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase; Y9449Q51XH / Bezafibrate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-minor] Adult. Aged. Antigens, CD / chemistry. Cell Adhesion Molecules / chemistry. Female. Humans. Indium Radioisotopes / pharmacokinetics. Kinetics. Leukemia, Myeloid, Acute / radiotherapy. Male. Middle Aged. Models, Statistical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiopharmaceuticals / pharmacokinetics. Yttrium Radioisotopes / pharmacokinetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19820266.001).

[ISSN] 1361-6560

[Journal-full-title] Physics in medicine and biology

[ISO-abbreviation] Phys Med Biol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.

The purpose of the study was to evaluate prognostic value of immunophenotype in aggressive Non-Hodgkin's lymphoma.

87 patients with immunohistologically confirmed diagnosis of aggressive Non-Hodgkin's lymphoma according to the WHO classification (2001) were under observation.

Overall survival was calculated from the date of diagnosis to the last follow-up or death regardless of the cause.

17 patients out of 87 were diagnosed as T-cell lymphomas.

Overall survival in patients with IPI greater than 2 (poor prognosis) was shorter for T-cell lymphomas (7,6 months) in comparison with B-cell lymphomas (17,3 months) (p<0,001).

T-cell phenotype should be considered as an independent factor that strongly influences the survival for patients with diagnosis of aggressive non-Hodgkin's lymphomas.

Besides petipherial T-cell lymphomas occurs more frequently in the elderly, with advanced stage, frequent extranodal site involvement, and often detected high level of LDH compared with B-cell lymphomas.

[MeSH-major] B-Lymphocytes / immunology. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / mortality. T-Lymphocytes / immunology

[MeSH-minor] Adult. Humans. Middle Aged. Prognosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16783081.001).

[ISSN] 1512-0112

[Journal-full-title] Georgian medical news

[ISO-abbreviation] Georgian Med News

[Language] eng

[Publication-type] Journal Article

[Publication-country] Georgia (Republic)

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

As this approach is not always feasible in older patients and patients with graft-versus-host disease, central venous catheters play an increasing role in providing long-term vascular access for ECP.However, not all catheters are able to deliver the minimum flow rate of 7 ml/min for ECP.

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Flow Velocity. Equipment Design. Equipment Failure Analysis. Female. Graft vs Host Disease / drug therapy. Humans. Hydrostatic Pressure. In Vitro Techniques. Lymphoma, T-Cell, Cutaneous / drug therapy. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17888008.001).

[ISSN] 1610-0387

[Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

[ISO-abbreviation] J Dtsch Dermatol Ges

[Language] eng; ger

[Publication-type] Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.

In a retrospective analysis of 113 patients with primary myelodysplastic syndromes (MDS) diagnosed according to French-American-British (FAB) classification, we evaluated the prognostic impact of FAB and World Health Organisation (WHO) classifications, International Prognostic Scoring System (IPSS), and other clinical and laboratory variables.

At a median follow-up of 24 months, 22 patients (19.5 %) transformed to acute myelogenous leukaemia (AML).

In WHO classification, significant differences were observed in both OS and leukaemia free survival (LFS) between patients with RA/RARS and refractory cytopenia with multi-lineage dysplasia/refractory cytopenia with multi-lineage dysplasia and ringed sideroblasts (RCMD/RS-RCMD) (p = 0.0001).

[MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Classification. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Turkey / epidemiology. World Health Organization

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17613766.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In this editorial, Retrovirology's choice for best basic science "retrovirus paper of the year" and a perspective on challenges and responsibilities facing HIV-1 and HTLV-I research are presented.

[MeSH-major] Leukemia-Lymphoma, Adult T-Cell. Research

[MeSH-minor] Animals. Disease Models, Animal. HIV Infections / drug therapy. HIV Infections / epidemiology. HIV Infections / prevention & control. HIV-1 / pathogenicity. Human T-lymphotropic virus 1. Humans. Proteins / metabolism. Proteins / therapeutic use

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2004 Feb 26;427(6977):848-53 [14985764.001]

[Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]

[Cites] Retrovirology. 2004;1:9 [15169567.001]

[Cites] Retrovirology. 2004;1:2 [15169555.001]

[Cites] Retrovirology. 2004;1:46 [15620346.001]

(PMID = 15644139.001).

[ISSN] 1742-4690

[Journal-full-title] Retrovirology

[ISO-abbreviation] Retrovirology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Proteins; 0 / TRIM5(alpha) protein, rhesus monkey

[Other-IDs] NLM/ PMC544867

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.

BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.

This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.

RESULTS: Among the 27 tumor specimens, ten (37%) were EBV-positive.

In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.

Among the 10 patients who had additional BM slides available, there were 3 with BM involvement, and none showed EBV positive results on ISH.

EBV PCR of the BM mononuclear cells revealed one-positive case among 8 patients.

[MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology

[MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / virology. DNA, Viral / isolation & purification. Female. Humans. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Survival Analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]

[Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]

[Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]

[Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]

[Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]

[Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]

[Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]

[Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]

[Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]

[Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]

[Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]

[Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]

[Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]

[Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]

[Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]

[Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]

[Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]

[Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]

[Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]

[Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]

[Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]

[Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]

(PMID = 18363277.001).

[ISSN] 1226-3303

[Journal-full-title] The Korean journal of internal medicine

[ISO-abbreviation] Korean J. Intern. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Chemical-registry-number] 0 / DNA, Viral

[Other-IDs] NLM/ PMC2686953

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Induction immunosuppressive therapy with the anti-T-cell antibody Thymoglobulin decreases the incidence of acute rejection in adult kidney transplant (KTx) recipients, but limited data are available for pediatric KTx recipients.

RESULTS: Overall, the incidence of acute rejection was lower in Thymoglobulin recipients versus ATGAM recipients (33% vs. 50%, P=0.02).

Epstein-Barr virus (EBV) infection was higher in Thymoglobulin recipients versus ATGAM recipients (8% vs. 3%, P=0.002).

But the two groups did not significantly differ in patient and graft survival rates, incidence of chronic rejection, EBV lymphoma, or other infection.

CONCLUSIONS: Thus, Thymoglobulin induction was associated with a decreased incidence of acute rejection and an increased incidence of EBV infection in pediatric KTx recipients.

MedlinePlus Health Information. consumer health - Kidney Transplantation.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15849550.001).

[ISSN] 0041-1337

[Journal-full-title] Transplantation

[ISO-abbreviation] Transplantation

[Language] eng

[Grant] United States / NIDDK NIH HHS / DK / DK13083

[Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Antilymphocyte Serum

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary laryngeal T/NK-cell lymphoma, nasal-type: an unusual location for an aggressive subtype of extranodal lymphoma.

Most of them are extramedullary plasmocytomas, diffuse large B-cell lymphomas, or MALT-type marginal zone B-cell lymphomas.

T- or NK-cell lymphomas have rarely been reported in this location.

The diagnosis of laryngeal lymphomas is a challenge, due to the absence of clinical and gross differential criteria.

We present hereby a primary laryngeal T/NK-cell lymphoma, nasal-type.

Polychemotherapy was administrated with initial partial response, but rapid local progression and exitus followed six months after the diagnosis.

The extranodal T/NK-cell lymphoma, nasal-type is a very aggressive subtype of extranodal lymphoma, usually located in the nasal cavity or in nearby sites.

The prognosis of extranasal cases of this type of lymphoma is poor, even when they are diagnosed in localized stages.

[MeSH-major] Killer Cells, Natural / pathology. Laryngeal Neoplasms / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis

[MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Fatal Outcome. Humans. Laryngoscopy. Male. Severity of Illness Index. Tomography, X-Ray Computed

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Otolaryngol. 1996 Sep-Oct;17(5):332-4 [8870939.001]

[Cites] Pathol Res Pract. 1995 Mar;191(2):130-8 [7567682.001]

[Cites] Cancer. 1996 May 15;77(10):2137-49 [8640683.001]

[Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]

[Cites] Cancer. 1979 Apr;43(4):1527-32 [445348.001]

[Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]

[Cites] Otolaryngol Head Neck Surg. 1999 Sep;121(3):335-6 [10471889.001]

[Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):1037-40 [9738818.001]

[Cites] Leuk Lymphoma. 1999 Oct;35(3-4):397-401 [10706465.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2005;:267-77 [16304391.001]

[Cites] Leuk Lymphoma. 2003 Jun;44(6):1053-7 [12854909.001]

[Cites] Laryngoscope. 1997 Nov;107(11 Pt 1):1502-6 [9369397.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2006;:331-7 [17124080.001]

[Cites] J Laryngol Otol. 1989 Oct;103(10):955-60 [2685150.001]

[Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]

[Cites] Blood. 1998 Mar 1;91(5):1723-31 [9473239.001]

[Cites] Hum Pathol. 1990 Oct;21(10):1041-50 [2210727.001]

[Cites] Head Neck. 2001 Aug;23(8):625-8 [11443744.001]

(PMID = 17955253.001).

[ISSN] 0937-4477

[Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

[ISO-abbreviation] Eur Arch Otorhinolaryngol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Unusual cyclin D1 positive marginal zone lymphoma of mediastinum.

We report a case of 43-yr-old Caucasian female with an unusual, cyclin D1 positive marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) type of the mediastinum.

They occur mainly in Asian females with a history of coexisting autoimmune disease.

The diagnosis was based on histopathological examination only.

Our final diagnosis of MZL was made by combined evaluation of histopathology (HP), immunohistochemistry (IH), flow cytometry (FCM), fluorescence in situ hybridization (FISH), and molecular biology studies.

We found a positive cyclin D1 reaction by IH and cyclin D1 mRNA (CCND1) overexpression by reverse transcription polymerase chain reaction (RT-PCR).

Very high cyclin D1 to beta-actin mRNA ratio in this case was comparable with the ratio, characteristic for mantle cell lymphoma (MCL).

However, there was no translocation t(11;14) found by FISH and an immunophenotype by IH and FCM was consistent with MZL ruling out MCL diagnosis.

In addition, our case differs from other, previously reported thymic MZL lymphoma cases by no autoimmune disease association, Caucasian origin, and the absence of the plasmacytic differentiation on both HP/IH.

[MeSH-major] Cyclin D1 / biosynthesis. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell, Marginal Zone / metabolism. Mediastinal Neoplasms / metabolism

[MeSH-minor] Adult. Female. Flow Cytometry / methods. Humans. Immunohistochemistry / methods. Immunophenotyping. In Situ Hybridization, Fluorescence / methods. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Models, Biological. Translocation, Genetic

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1992 Mar 15;69(6):1347-55 [1540872.001]

[Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E76-9 [12562258.001]

[Cites] Semin Diagn Pathol. 1991 Feb;8(1):2-13 [2047614.001]

[Cites] Blood. 1997 Oct 15;90(8):2863-92 [9376567.001]

[Cites] Med Oncol. 2005;22(3):319-23 [16110143.001]

[Cites] J Mol Diagn. 2004 May;6(2):84-9 [15096562.001]

[Cites] Am J Pathol. 1998 Dec;153(6):1969-76 [9846986.001]

[Cites] Am J Pathol. 2002 Apr;160(4):1435-43 [11943727.001]

[Cites] Am J Pathol. 1994 Jul;145(1):86-96 [7518196.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1985-9 [8410123.001]

[Cites] Lancet Oncol. 2004 Feb;5(2):107-18 [14761815.001]

[Cites] Blood. 1987 Apr;69(4):1087-95 [3103712.001]

[Cites] Am J Pathol. 1991 Mar;138(3):591-9 [1900388.001]

[Cites] Ann Oncol. 1996 Mar;7(3):251-6 [8740788.001]

[Cites] J Exp Med. 1980 Nov 1;152(5):1430-5 [6968814.001]

[Cites] J Appl Genet. 2002;43(4):545-53 [12441639.001]

[Cites] J Clin Oncol. 1987 Mar;5(3):407-12 [3819806.001]

[Cites] Blood. 2000 Apr 1;95(7):2253-61 [10733493.001]

[Cites] Am J Surg Pathol. 1990 Apr;14(4):342-51 [1690952.001]

[Cites] Am J Clin Pathol. 2000 Jun;113(6):784-91 [10874878.001]

[Cites] Genes Chromosomes Cancer. 1993 Oct;8(2):80-7 [7504521.001]

[Cites] Mod Pathol. 2002 May;15(5):556-64 [12011261.001]

[Cites] Am J Med. 1980 Apr;68(4):509-14 [6892753.001]

(PMID = 17018901.001).

[ISSN] 1559-131X

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 136601-57-5 / Cyclin D1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.

We sought to re-examine the prognostic utility of (1) the number of extranodal sites of disease involvement, and (2) a primary extranodal presentation in patients with DLBCL treated with immunochemotherapy.

In the R-CHOP group, extranodal involvement as defined by the International Prognostic Index (>or=2 sites) was not prognostic on multivariate analysis, but the presence of any extranodal involvement (>or=1 site) was associated with decreased progression-free survival (HR 1.6, 95% CI 1.1-2.4, p = 0.024) and overall survival (HR 1.8, 95% CI 1.1-2.7, p = 0.011).

There was no difference in outcome between patients with primary extranodal and nodal DLBCL, and no primary site of involvement was associated with an inferior outcome.

In patients with DLBCL treated with R-CHOP, the presence of extranodal disease remains prognostic, whereas a primary extranodal presentation did not affect outcome.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy

[MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Rituximab. Survival Rate. Tissue Distribution. Vincristine / administration & dosage. Young Adult

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20795790.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1.

Human T-cell lymphotropic virus type 1 (HTLV-1), the cause of adult T-cell leukemia/lymphoma (ATLL), transforms CD4(+) T cells to permanent growth through its transactivator Tax.

HTLV-1-transformed cells share phenotypic properties with memory and regulatory T cells (T-reg).

This led us to determine cAMP levels in HTLV-1-transformed cells.

We found elevated cAMP concentrations as a consistent feature of all HTLV-1-transformed cell lines, including in vitro-HTLV-1-transformed, Tax-transformed, and patient-derived cells.

We found specific downregulation of the cAMP-degrading phosphodiesterase 3B (PDE3B) in HTLV-1-transformed cells, which was independent of Tax in transient expression experiments.

Overexpression of PDE3B led to a decrease of cAMP in HTLV-1-transformed cells.

Decreased expression of PDE3B was associated with inhibitory histone modifications at the PDE3B promoter and the PDE3B locus.

This shows that HTLV-1-transformed cells assume biological features of long-lived T-cell populations that potentially contribute to viral persistence.

[MeSH-major] Cell Transformation, Viral. Cyclic AMP / metabolism. HTLV-I Infections / metabolism. Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism

[MeSH-minor] Cell Line, Transformed. Cells, Cultured. Cyclic Nucleotide Phosphodiesterases, Type 3 / genetics. Cyclic Nucleotide Phosphodiesterases, Type 3 / metabolism. Gene Products, tax / genetics. Gene Products, tax / metabolism. Humans. T-Lymphocytes / metabolism. T-Lymphocytes / virology

SciCrunch. ArrayExpress: Data: Microarray .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochem Pharmacol. 1999 Sep 15;58(6):935-50 [10509746.001]

[Cites] Cancer Res. 1986 Sep;46(9):4458-62 [2873886.001]

[Cites] Cancer Sci. 2005 Aug;96(8):527-33 [16108835.001]

[Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]

[Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]

[Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]

[Cites] Oncogene. 2005 Sep 5;24(39):6035-46 [16155610.001]

[Cites] Int Immunol. 2006 Feb;18(2):269-77 [16361311.001]

[Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]

[Cites] Blood. 2006 Jun 1;107(11):4491-9 [16467195.001]

[Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]

[Cites] J Leukoc Biol. 2006 Oct;80(4):880-8 [16888088.001]

[Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]

[Cites] J Virol. 2007 Mar;81(5):2524-30 [17151105.001]

[Cites] Nature. 2007 Feb 15;445(7129):771-5 [17220874.001]

[Cites] Nature. 2007 Feb 22;445(7130):936-40 [17237761.001]

[Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]

[Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]

[Cites] J Exp Med. 2007 Jun 11;204(6):1303-10 [17502663.001]

[Cites] J Biol Chem. 2007 Jun 29;282(26):18750-7 [17449469.001]

[Cites] J Immunol. 2008 Jan 15;180(2):931-9 [18178833.001]

[Cites] J Gen Physiol. 2008 Apr;131(4):293-305 [18378798.001]

[Cites] Blood. 2008 May 1;111(9):4741-51 [18276843.001]

[Cites] Blood. 2000 Jan 1;95(1):30-8 [10607681.001]

[Cites] FEBS Lett. 2001 Sep 7;505(1):136-40 [11557056.001]

[Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]

[Cites] Mol Cell Biol. 1985 Dec;5(12):3610-6 [3915782.001]

[Cites] Nature. 1988 Oct 20;335(6192):738-40 [3262832.001]

[Cites] J Virol. 1989 Apr;63(4):1604-11 [2538645.001]

[Cites] J Virol. 1989 Aug;63(8):3220-6 [2501514.001]

[Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]

[Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68 [7531462.001]

[Cites] J Exp Med. 1995 Mar 1;181(3):985-92 [7532686.001]

[Cites] Clin Diagn Lab Immunol. 1995 May;2(3):349-55 [7545080.001]

[Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]

[Cites] Retrovirology. 2008;5:76 [18702816.001]

[Cites] FEBS Lett. 2008 Oct 29;582(25-26):3614-8 [18835269.001]

[Cites] Blood. 2008 Nov 1;112(9):3788-97 [18689544.001]

[Cites] Retrovirology. 2008;5:100 [19014482.001]

[Cites] Int J Cancer. 2009 Nov 15;125(10):2375-82 [19544530.001]

[Cites] Virus Genes. 2001 Dec;23(3):263-71 [11778694.001]

[Cites] Blood. 2002 May 1;99(9):3383-9 [11964307.001]

[Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):710-8 [12209131.001]

[Cites] Virology. 2003 Dec 5;317(1):136-45 [14675632.001]

[Cites] Cancer Res. 2004 Mar 15;64(6):2039-46 [15026341.001]

[Cites] J Virol. 2004 Sep;78(18):9814-9 [15331715.001]

[Cites] J Immunol. 1971 Nov;107(5):1489-92 [4330163.001]

[Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]

[Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]

[Cites] Gan. 1984 Sep;75(9):752-5 [6094296.001]

[Cites] J Gen Virol. 1985 Aug;66 ( Pt 8):1825-9 [2991447.001]

[Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]

[Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]

[Cites] Biochem Biophys Res Commun. 2005 Jul 1;332(2):569-84 [15896717.001]

(PMID = 20573814.001).

[ISSN] 1098-5514

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] eng

[Databank-accession-numbers] GEO/ GSE17718

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Gene Products, tax; 0 / tax protein, Human T-lymphotrophic virus 1; E0399OZS9N / Cyclic AMP; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 3; EC 3.1.4.17 / PDE3B protein, human

[Other-IDs] NLM/ PMC2918996